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Abstract  43 
Background & Aims: There is limited evidence that a diet low in fermentable oligosaccharides, 44 
disaccharides, monosaccharides, and polyols (FODMAPs) reduces gut symptoms in quiescent 45 
inflammatory bowel disease (IBD). We performed a randomized, controlled trial to investigate the effects 46 
of a low-FODMAP diet on persistent gut symptoms, the intestinal microbiome, and circulating markers of 47 
inflammation in patients with quiescent IBD. 48 
 49 
Methods: We performed a single-blind trial of 52 patients with quiescent Crohn’s disease or ulcerative 50 
colitis and persistent gut symptoms at 2 large gastroenterology clinics in the United Kingdom. Patients 51 
were randomly assigned to groups that followed a diet low in FODMAPs (n=27) or a control diet (n=25), 52 
with dietary advice, for 4 weeks. Gut symptoms and health-related quality of life were measured using 53 
validated questionnaires. Stool and blood samples were collected at baseline and end of trial. We assessed 54 
fecal microbiome composition and function using shotgun metagenomic sequencing and phenotypes of 55 
T cells in blood using flow cytometry.  56 
 57 
Results: A higher proportion of patients reported adequate relief of gut symptoms following the low-58 
FODMAP diet (14/27, 52%) than the control diet (4/25, 16%, P=.007). Patients had a greater reduction in 59 
irritable bowel syndrome severity scores following the low-FODMAP diet (mean reduction of 67; standard 60 
error, 78) than the control diet (mean reduction of 34; standard error, 50), although this difference was 61 
not statistically significant (P=.075). Following the low-FODMAP diet, patients had higher health-related 62 
quality of life scores (81.9±1.2) than patients on the control diet (78.3±1.2, P=.042). A targeted analysis 63 
revealed that in stool samples collected at the end of the study period, patients on the low-FODMAP diet 64 
had significantly lower abundance of Bifidobacterium adolescentis, B longum, and Faecalibacterium 65 
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prausnitzii than patients on control diet. However, microbiome diversity and markers of inflammation did 66 
not differ significantly between groups. 67 
 68 
Conclusions: In a trial of the low-FODMAP diet vs a control diet in patients with quiescent IBD, we found 69 
no significant difference after 4 weeks in change in irritable bowel syndrome severity scores, but 70 
significant improvements in specific symptom scores and numbers reporting adequate symptom relief. 71 
The low-FODMAP diet reduced fecal abundance of microbes believed to regulate the immune response, 72 
compared with the control diet, but had no significant effect on markers of inflammation. We conclude 73 
that a 4-week diet low in FODMAPs is safe and effective for managing persistent gut symptoms in patients 74 
with quiescent IBD. www.isrctn.com no: ISRCTN17061468 75 
 76 
KEY WORDS:  CD, UC, IBS, HR-QOL 77 
  78 
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Introduction 79 
An estimated 35% of patients with inflammatory bowel disease (IBD) experience gut symptoms despite 80 
having quiescent disease with minimal objective evidence of gastrointestinal (GI) inflammation (1) The 81 
etiology of these gut symptoms in quiescent IBD is unclear but they are hypothesized to relate to 82 
coexistent irritable bowel syndrome (IBS), the legacy of previous GI inflammation on gut function, 83 
persistent unidentified low-grade inflammation, or the psychological impact of IBD (2). These persistent 84 
gut symptoms have a significant impact upon health-related quality of life (HR-QOL) (3) and pose a 85 
treatment dilemma since escalating immune-modulating agents is likely to be ineffective. Limited 86 
evidence exists to support the pharmacological management of persistent gut symptoms in quiescent IBD.  87 
Dietary fermentable carbohydrates increase small intestinal water through osmotic potential (e.g. 88 
fructose, mannitol) and colonic gas through microbial fermentation (e.g. fructans, galacto-89 
oligosaccharides) (4). Randomized, crossover re-challenge trials, which overcome the limitations of 90 
masking and confounding in dietary intervention studies, have shown that fermentable oligosaccharides, 91 
disaccharides, monosaccharides and polyols (FODMAPs) can induce gut symptoms in both IBS and 92 
quiescent IBD (5, 6).  93 
Dietary restriction of FODMAPs (low FODMAP diet) is thought to ameliorate functional gut symptoms by 94 
reducing diet-induced luminal water and colonic gas and consequently, luminal distension, in those with 95 
visceral hypersensitivity (7, 8). Randomized, placebo-controlled trials of low FODMAP diet in IBS, delivered 96 
through a feeding study or as dietary advice, reported improvement of gut symptoms in 70% and 57% of 97 
patients, respectively (9, 10). In IBD, retrospective and prospective uncontrolled studies suggest potential 98 
benefit of low FODMAP diet as a therapy for persistent gut symptoms (11, 12) and more recently, a 99 
randomized controlled trial reported that gut symptoms improved in 81% of patients with IBD during low 100 
FODMAP diet compared with 46% in control (13). However, the trial was unblinded, therefore cannot 101 
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account for the considerable placebo response that occurs in both IBS and IBD (14) particularly in response 102 
to diet interventions. 103 
Low FODMAP diet reduces fermentable substrate in the colon, and in IBS this alters microbiome 104 
composition, resulting in reduced Bifidobacteria (9, 15) and Faecalibacterium prausnitzii (16) abundance. 105 
Bifidobacteria abundance in the mucosal microbiome is positively associated with the proportion of IL-10 106 
expressing dendritic cells in Crohn’s disease (CD) (17). Furthermore, low abundance of F. prausnitzii is 107 
associated with active IBD, and is associated with greater post-operative relapse at 6 months in CD (18-20). 108 
Therefore, the microbiological impact of low FODMAP diet could theoretically have an adverse effect on 109 
the mucosal immune response and disease course in IBD, but to date has only been investigated in one 110 
trial of nine patients with Crohn’s disease (21).  111 
Accordingly, clinical trials to establish the therapeutic benefit of low FODMAP diet in managing gut 112 
symptoms in IBD must be placebo-controlled and must assess the impact on the microbiome, GI 113 
inflammation and disease activity. To this end, we designed a randomized controlled trial to investigate 114 
the effects of low FODMAP dietary advice compared to placebo (sham) dietary advice on persistent gut 115 
symptoms, disease activity, GI microbiome and peripheral T-cell phenotypes in quiescent IBD. 116 
Methods  117 
Study design and participants 118 
Patients were recruited from two large gastroenterology clinics in London, United Kingdom in a multi-119 
center, randomized, parallel, single-blinded, placebo-controlled trial. Eligible patients were aged ≥18 120 
years, with quiescent CD or ulcerative colitis (UC), experiencing ongoing gut symptoms and were naïve to 121 
low FODMAP diet. Quiescent IBD was defined by all of the following: physician global assessment; stable 122 
medications; no IBD flare in the previous 6 months; fecal calprotectin <250 μg/g; and serum CRP <10 mg/L. 123 
The threshold for fecal calprotectin was chosen according to evidence proposing optimal sensitivity and 124 
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specificity for detecting endoscopically quiescent disease (22). Ongoing gut symptoms were required to 125 
meet the Rome III criteria for either diarrhea predominant (IBS-D), mixed subtype (IBS-M) or unsubtyped 126 
IBS (IBS-U), functional bloating (FB) or functional diarrhea (FD), experiencing abdominal pain, bloating 127 
and/or diarrhea on 2 days during the baseline screening week and reporting inadequate relief of GI 128 
symptoms (23).  129 
Patients with dose changes of azathioprine, mercaptopurine, methotrexate or biologics in the preceding 130 
12 weeks, oral 5-aminosalicylic acid in the preceding 4 weeks or antibiotics, probiotics or prebiotics in the 131 
preceding 8 weeks were excluded. Patients with pure perianal CD, a current stoma, previous extensive GI 132 
resection or a current stricture were excluded. Patients with established bile acid malabsorption (BAM) 133 
were excluded since gut symptoms relating directly to BAM may not be modifiable by low FODMAP diet. 134 
Patients with constipation-predominant symptoms were excluded, since low FODMAP diet could 135 
exacerbate this symptom. Patients with self-reported lactose intolerance were included if they continued 136 
to experience gut symptoms despite low lactose diet. Patients were excluded if they had significant 137 
comorbidities, or if they were pregnant or lactating.  138 
Research ethics committee approval was received from the London Dulwich ethics committee (Reference 139 
15/LO/1684) and the trial was registered on the ISRCTN registry (ISRCTN17061468) prior to participant 140 
recruitment. All authors had access to the study data and reviewed and approved the final manuscript. 141 
Randomization and masking 142 
A random allocation sequence was prepared online (www.sealedenvelope.com) by an independent 143 
researcher using block randomization, with a 1:1 ratio of low FODMAP to placebo sham diet. 144 
Randomization was stratified by diagnosis (CD or UC) and fecal calprotectin at screening (≤100 μg/g and 145 
101-249 μg/g). Allocation sequences were sealed in opaque envelopes.  146 
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Participants were blinded to diet allocation and informed that both diets would change the types of 147 
carbohydrates consumed, but that one was the diet under investigation, while the other was a sham diet. 148 
The terms ‘fermentable carbohydrates’, ‘low FODMAP diet’ or the mechanisms of the diet were not 149 
mentioned to participants.  150 
Study visits 151 
Patients were identified via gastroenterology clinics and referrals to the dietetic department for the 152 
management of gut symptoms in quiescent IBD. Fecal calprotectin and CRP were assessed during 153 
screening and a 7-day food, stool and GI symptom diary was completed, from which the frequency and 154 
severity of gut symptoms were assessed for eligibility. Eligible participants attended a baseline visit, during 155 
which questionnaires were completed and stool and blood samples were collected to assess microbiome 156 
and immunology. Patients were randomized to follow either low FODMAP or sham dietary advice for 4 157 
weeks and completed a 7-day food, stool and GI symptom diary in the final week. Finally, all outcomes 158 
were re-assessed at an end of trial visit which was conducted within 3-days of the end of the 4-week 159 
period, during which diet allocation was continued.  160 
Intervention and control 161 
Low FODMAP and sham dietary advice were provided to all participants by the same research dietician 162 
(SC) with extensive training and experience in delivering low FODMAP diet. The diet involves the 163 
restriction of dietary fructans, galacto-oligosaccharides (GOS), lactose, fructose in excess of glucose, and 164 
polyols, including sorbitol and mannitol, and is described in detail elsewhere (24). The selection of an 165 
appropriate control group and difficulties in masking intervention and control are challenging in dietary 166 
intervention studies, but for research on dietary advice (which most closely mimics clinical practice), 167 
‘sham’ dietary advice is considered gold standard (25). The sham diet in this trial aimed to provide patients 168 
in the control group with an exclusion diet of similar intensity and burden to low FODMAP diet, while not 169 
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impacting upon nutrient, fiber or FODMAP intakes. The sham diet has been used successfully in the only 170 
randomized, placebo-controlled trial of low FODMAP dietary advice in IBS (9). Dietary counselling for both 171 
low FODMAP diet and sham diet lasted approximately 20 minutes and both groups received written 172 
information.  173 
Dietary compliance to both diets was encouraged at weekly telephone contact. Compliance with the diet 174 
was assessed at end of trial using the single question: ‘During the 4-week trial I have followed the diet…’: 175 
never/rarely (<25% of the time), sometimes (25-50% of the time), frequently (51-75% of the time) or 176 
always (76-100% of the time). For the purposes of per protocol analysis, compliance was defined as 177 
following diet ‘always’ (76-100% of the time) during the trial. 178 
Outcomes 179 
The primary outcome was the change in IBS Severity Scoring System (IBS-SSS) during the trial, compared 180 
between groups. Pre-defined secondary outcomes included other measures of gut symptoms (total IBS-181 
SSS score, proportion of patients achieving a 50-point IBS-SSS reduction, global symptom question; GSQ, 182 
GI symptom rating scale; GSRS), disease-specific HR-QOL, stool frequency and consistency, clinical disease 183 
activity, inflammatory markers, dietary intake, microbiome composition and function, short chain fatty 184 
acid (SCFA) concentrations and peripheral T-cell phenotype. All pre-defined secondary outcomes were 185 
included in the study protocol prior to study commencement. Exploratory outcomes included responders 186 
defined as achieving at least a 50% reduction in total IBS-SSS score during the trial. 187 
Clinical outcomes  188 
Gut symptoms were evaluated at baseline and end of trial using the IBS-SSS (26) and the GSRS (27). The GSQ 189 
was used to assess adequate relief of GI symptoms at end of trial. Disease-specific HR-QOL was assessed 190 
using the UK-specific IBD questionnaire (IBDQ) (28). Stool frequency and consistency were measured using 191 
the Bristol Stool Form Scale (BSFS) (29) which has undergone extensive validation (30). 192 
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Disease activity 193 
At baseline and end of trial, disease activity was assessed using the Harvey Bradshaw Index for CD (31) and 194 
the Partial Mayo Score for UC (32). Patient-perceived IBD control was assessed in all patients using the IBD 195 
Control questionnaire (33). Fecal calprotectin concentrations were determined using enzyme-linked 196 
immunosorbent assay and serum CRP concentrations were determined using a standard assay in the 197 
hospital laboratory.  198 
Dietary intake 199 
Dietary intake was measured at baseline and end of trial using 7-day food records. A nutrient composition 200 
database (Nutritics, Dublin, Ireland) was used for assessment of nutrient and fiber intakes, and into a 201 
bespoke database to assess FODMAP intake (Monash University, Melbourne, Australia). 202 
Microbiome composition, function and SCFA 203 
A quantitative metagenomic pipeline following the International Human Microbiome Standards (IHMS; 204 
http://www.microbiome-standards.org) was used to assess GI microbiome composition and function (34). 205 
A fresh stool sample was collected at baseline and end of trial and stored immediately on ice. The sample 206 
was homogenized and stored at -80°C (IHMS SOP 04 V2). DNA extraction was performed following IHMS 207 
SOP 07 V2. DNA was quantitated using Qubit Fluorometric Quantitation (ThermoFisher Scientific, 208 
Waltham, US) and qualified on a Fragment Analyzer (Agilent Technologies, Santa Clara, US). The 209 
sequencing library was built using 3 µg of high molecular weight DNA (>10 kbp). DNA was sheared into 210 
fragments of approximately 150 bp using an ultrasonicator (Covaris, Woburn, US) and fragment library 211 
construction was performed using the 5500 Solid Fragment 48 Library Core Kit (ThermoFisher Scientific, 212 
Waltham, US). Fragment libraries were sequenced using the Ion Proton Sequencer (ThermoFisher 213 
Scientific, Waltham, US), generating a minimum of 20 million high-quality reads of 150 bp per library. 214 
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Gene abundance profiling was performed by mapping high-quality reads to the 9.9 million gene integrated 215 
reference catalog of the human microbiome (35) using Bowtie 2 with a 95% identity threshold (36). The gene 216 
abundance profiling table was generated via a two-step procedure using METEOR. The gene abundance 217 
table was processed for rarefaction and normalization using the MetaOMineR (momr) R package (37). To 218 
decrease technical bias due to different sequencing depth and artifacts of sample size on low abundance 219 
genes, read counts were rarefied to 14 million reads per sample by random sampling without 220 
replacement. The resulting rarefied gene abundance table was normalized according to the FPKM 221 
(fragments per kilobase of exon model per million reads mapped) strategy. Metagenomic species (MGS) 222 
are co-abundant gene groups with more than 500 genes corresponding to microbial species. Taxonomical 223 
annotation was performed on all genes by sequence similarity using NCBI blast N; a species-level 224 
assignment was given if >50% of the genes matched the same reference genome of the NCBI database 225 
(November 2016 version) at a threshold of 95% of identity and 90% of gene length coverage. The 226 
remaining MGS were assigned to a given taxonomic level from genus to superkingdom level, where more 227 
than 50% of their genes had the same assignment level. Microbial gene richness (gene count) was 228 
calculated by counting the number of genes detected at least once in a given sample. MGS richness (MGS 229 
count) was calculated directly from the MGS abundance matrix.  230 
The functional analysis is led using a MGP pipeline FantoMET (unpublished). Genes of the catalog were 231 
annotated using KEGG82 database. KEGG and GMM modules (Gut Metabolic Module) were reconstructed 232 
in each metagenomic species using their pathway structures (and potential alternative pathways) (39). 233 
Abundance of each detected module in a metagenomic species corresponds to the abundance of the 234 
metagenomic species as described in the method section. Abundance of a given module in a sample is 235 
computed as the sum of the abundances of the module in each metagenomic species. 236 
Fecal short-chain fatty acid (SCFA) concentrations were assessed using a standard gas-liquid 237 
chromatography (GLC) protocol, using the 9890A series GLC system (Agilent Technologies, Santa Clara, 238 
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US) and fecal pH was measured using a pH probe (InLab®, Mettler Toledo probe and FE20 FiveEasy™ 239 
Benchtop pH meter). 240 
Peripheral T-cell phenotype  241 
Blood samples were collected at baseline and end of trial in sodium-heparin vacutainer tubes (BD 242 
Bioscience) and processed within 3 hours. Whole blood was labelled with fluorescently conjugated 243 
monoclonal antibodies to detect CD3 T-cells, as well as naïve (CD45RA+) and effector/memory (CD45RA-244 
) CD4 and CD8 T-cells, and Vδ2 unconventional T-cells. The gut-homing integrin α4β7 was detected by 245 
labelling with anti-β7 (40, 41). The BD FACSCanto II flow cytometer was used to acquire data, the FACS DIVA 246 
software (BD Bioscience) used to collect the data, and Winlist software (Verity, Topsham, ME, US) used to 247 
analyze the data.  248 
Statistical analysis 249 
Sample size was calculated based on the primary outcome, with expected values taken from a previous 250 
trial in IBS comparing low FODMAP (mean IBS-SSS change -117 points, SD 86) with sham advice (-44 points, 251 
SD 72) (9). With a power of 80% and two-sided significance of 5%, a sample size of 44 participants was 252 
required. Assuming 15% attrition, a sample size of 52 participants (26 per group) was required.  253 
Pre-planned comparisons of the primary (change in IBS-SSS score during trial) and secondary outcomes 254 
between the low FODMAP and sham diet at end of trial were performed. Sub-group analysis for UC and 255 
CD were pre-planned in the protocol and were conducted for all outcomes. The proportion of participants 256 
achieving at least a 50% reduction in total IBS-SSS score during the trial was an exploratory outcome 257 
compared between the diet groups.  258 
Data on gut symptoms, HR-QOL, disease activity, inflammatory markers and peripheral T-cell phenotype 259 
were analyzed intention-to-treat (ITT), followed by per protocol (PP), the latter consisting of patients who 260 
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completed the trial, did not violate protocol and were ‘always’ compliant with dietary intervention. Data 261 
on microbiome composition and SCFA concentrations are presented for the PP population.  262 
Clinical variables, SCFA and T-cell phenotype data were compared between groups at end of trial using 263 
ANCOVA, with corresponding baseline values as a covariate, and are therefore presented as estimated 264 
marginal mean (standard error of the mean; SEM). Categorical variables, presented as number (%), were 265 
compared between groups using the Chi-squared or Fisher’s Exact Test. Statistical analysis was performed 266 
using SPSS Version 24.0 (IBM, Chicago, US).  267 
Differences in gut microbial alpha and beta diversity between low FODMAP and sham diet were calculated 268 
using Mann-Whitney tests while comparisons of taxonomical and functional composition were assessed 269 
using likelihood ratio tests. Microbiome composition was analyzed using two approaches. First, an 270 
untargeted analysis of the relative abundance of all characterized bacteria (a total of 616 species and 271 
strains) was performed. Then, a targeted analysis of the specific species and strains of interest with 272 
regards to the low FODMAP diet or IBD was performed. P-values were adjusted for multiple comparisons 273 
using the Benjamini Hochberg approach for both the untargeted and targeted analyses. Microbiome 274 
bioinformatics was performed using R version 1.0.136 (Vienna, Austria). Differences are stated as 275 
statistically significant where P≤.05. 276 
Results  277 
Recruitment occurred between February 2016 and May 2017. Of 155 screened participants, 103 were 278 
ineligible (Figure 1). Fifty-two patients were randomized to low FODMAP (n=27) and sham diets (n=25). 279 
All 52 randomized patients were included in the ITT analysis. Six participants were withdrawn; two 280 
withdrew consent during the trial (one in each group), one became pregnant (sham diet), two commenced 281 
steroids due to an IBD flare (one in each group), and one commenced antibiotics for an unrelated infection 282 
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(low FODMAP diet). Of the 46 patients completing the trial, three were non-compliant with the diet, 283 
leaving 43 participants (21 low FODMAP diet, 22 sham diet) in the PP analysis.  284 
Baseline characteristics are displayed in Table 1. There were no differences in IBD characteristics between 285 
diet groups. However, participants in low FODMAP group were younger (33, SD 11 years) than in the sham 286 
diet (40, SD 13 years, P=.031). There was a greater proportion of participants of white ethnicity in low 287 
FODMAP (25/27, 92%) than the sham group (19/25, 76%, P=.029).  288 
Adverse events 289 
There were six adverse events during the trial. Two participants had an IBD relapse (one in each group) 290 
and one commenced antibiotics unrelated to IBD (low FODMAP). All three participants were withdrawn 291 
from the trial due to meeting exclusion criteria. One participant reported a worsening of abdominal pain 292 
lasting two days that resolved (sham diet). Flu-like symptoms and sinusitis were reported (one in each 293 
group), both of which were unrelated to the diet. No serious adverse events were recorded. 294 
Gut symptoms and HR-QOL 295 
There was a greater reduction in total IBS-SSS score following low FODMAP (-67, SEM 12) compared to 296 
sham diet (-34, SEM 13), although the difference was not statistically significant (P=.075) (Table 2). There 297 
was a significantly lower score for bloating severity (IBS-SSS) following low FODMAP (23, SEM 3) than 298 
sham diet (34, SEM 3, P=.021). The PP analysis showed similar results to the ITT analysis for all IBS-SSS 299 
outcomes. The exploratory analysis revealed that significantly more participants achieved a 50% reduction 300 
in IBS-SSS following low FODMAP (9/27, 33%) than sham diet (1/25, 4%, P=.012) (Table 2). 301 
Pre-defined sub-group analyses of UC (n=26) and CD (n=26) were performed for all clinical outcomes 302 
(Table 2). In UC, there was a significantly greater reduction in IBS-SSS score following low FODMAP 303 
compared to sham diet (P=.031), as well as a significantly lower end of trial IBS-SSS score (P=.031). In CD, 304 
15 
 
there was no difference in change in IBS-SSS score following low FODMAP compared to sham diet 305 
(P=.515), or in end of trial IBS-SSS score (P=.515).  306 
Significantly more patients reported adequate relief of gut symptoms following low FODMAP (14/27, 52%) 307 
than sham diet (4/25, 16%, P=.007). There were no differences in the proportion of patients reporting 308 
adequate relief between low FODMAP and sham diet in the sub-group analysis of UC (7/13, 54% vs. 2/13, 309 
15%, P=.097) or CD (7/14, 50% vs. 2/12, 17%, P=.110).  310 
The severity of flatulence, as measured using the GSRS, was significantly lower during low FODMAP (0.9, 311 
SEM 0.1) compared to sham diet (1.2, SEM 0.1, P=.035), however no other symptoms, including abdominal 312 
pain, were different between groups (Supplementary information). Significantly lower daily stool 313 
frequency was reported following low FODMAP (1.7, SEM 0.1) than sham diet (2.1, SEM 0.1, P=.012), but 314 
there was no difference in the proportion of stools of normal consistency (types 3-5) between low 315 
FODMAP (65% normal consistency, SEM 5%) and sham diet (69%, SEM 5%, P=.478) (Table 2).  316 
Total IBDQ score was significantly greater (indicating better HR-QOL) following low FODMAP (81.9, SEM 317 
1.2) than sham diet (78.3, SEM 1.2, P=.042). Specifically, the Bowel II domain score (effects of GI symptoms 318 
on HR-QOL) was significantly greater following low FODMAP (76.5, SEM 2.0) than sham diet (70.0, SEM 319 
2.1, P=.031). 320 
Disease activity  321 
At baseline, the majority of participants had CRP <5 mg/L (50/52, 96%) and fecal calprotectin <100 μg/g 322 
(43/52, 83%).  323 
In CD, there was no difference in HBI score between low FODMAP (3.2, SEM 0.4) and sham diet (3.4, SEM 324 
0.5, P=.814) at end of trial. In UC, there was no difference in Partial Mayo score between low FODMAP 325 
(0.2, SEM 0.2) and sham diet (0.2, SEM 0.2, P=.951). The IBD-control score demonstrated greater patient-326 
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perceived control of IBD following low FODMAP (88.3, SEM 4.3) compared to sham diet (74.3, SEM 4.5, 327 
P=.028), these differences were seen specifically in UC (94.2, SEM 6.6 vs. 71.3, SEM 6.6, P=.022) but not 328 
in CD (81.4, SEM 5.2 vs. 79.1, SEM 5.7, P=.768). 329 
Importantly, there was no difference in end of trial fecal calprotectin between low FODMAP (60.0 μg/g, 330 
SEM 9.4) and sham diet (59.6 μg/g, SEM 9.8, P=.976) or in serum CRP concentration between low FODMAP 331 
(2.0 mg/L, SEM 0.3) and sham diet (1.6 mg/L, SEM 0.3, P=.246).  332 
Further fecal calprotectin concentration data (including UC and CD sub-group analyses and baseline 333 
compared to end of trial comparisons) are presented in the Supplementary information. 334 
Dietary intake and compliance 335 
In low FODMAP and sham diet groups, 24/27 (88%) and 25/25 (100%) of participants reported following 336 
the diet ‘always’ (76-100% of the time) (P=.230). In support of high levels of self-reported compliance, 337 
intakes of fructans, GOS, lactose, excess fructose, sorbitol and mannitol were significantly lower in the 338 
low FODMAP compared to sham diet (Supplementary information).  339 
Seven-day food diaries revealed significantly lower energy, protein, fat, sugars, calcium, phosphorous and 340 
iodine intake in low FODMAP compared to sham diet (Supplementary information). There were no 341 
significant differences in intakes of any other nutrients between diet groups. 342 
Microbiome composition, function and SCFA 343 
An average of 22,690,418 sequencing reads of 150 bp were obtained for each sample, with an average 344 
14,310,652 reads mapping uniquely to the gene catalogue (67% of reads). 345 
There was no difference in gene count, species count, phyla distribution or any index of α-diversity or β-346 
diversity between diet groups at end of trial (Figure 2a-d). 347 
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Of 616 species present in more than 5% of subjects, the abundance of 29 species (4.7%) was significantly 348 
impacted (P≤.05) by the diet (untargeted microbiome analysis) (Figure 3). None of these remained 349 
significant when adjusted for multiple comparisons. In the targeted microbiome analysis (Table 3), relative 350 
abundance of total Bifidobacteria was not significantly different between low FODMAP and sham diet 351 
(P=.073), however Bifidobacterium longum (P=.005, Q=.017) and B. adolescentis (P=.003, Q=.017) were 352 
significantly lower, and B. dentium abundance was higher (P=.035, Q=.096) following the low FODMAP 353 
diet. Abundance of total F. prausnitzii species was significantly lower following low FODMAP compared to 354 
sham diet (P=.038). However, no F. prausnitzii strains were significantly lower and interestingly, F. 355 
prausnitzii SL3/3-M21/2 was higher following low FODMAP compared to sham diet (Table 3).  356 
Differences in microbial abundance in the UC and CD sub-group analyses are presented in supplementary 357 
information (Supplementary information). 358 
The metabolic potential of the microbiome was assessed using functional metagenomics. The abundance 359 
of 34 KO (KEGG orthology) groups were significantly different (P≤.05) between low FODMAP and sham 360 
diet groups (Figure 4). Among the modules significantly higher in abundance following low FODMAP 361 
compared to sham diet were cellobiose transport system and propionate production, and among modules 362 
lower in abundance were lactose and galactose degradation pathways and glutamate transport system 363 
and the putative zinc/manganese transport system. None of these remained significant following FDR 364 
correction.  365 
There were lower fecal concentrations of total SCFA following low FODMAP (398 mg/100g feces, SEM 37) 366 
compared to sham diet (505 mg/100g feces, SEM 36, P=.049) in the PP population. In UC, total SCFA were 367 
significantly lower following low FODMAP (386 mg/100g feces, SEM 53) than sham diet (553 mg/100g 368 
feces, SEM 55, P=.041). However, in CD there was no difference between diet groups (409 mg/100g feces, 369 
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SEM 51) and sham diet (463 mg/100g feces, SEM 46, P=.453). Individual SCFA concentrations and fecal pH 370 
in the ITT and PP populations, and in UC and CD, are provided in the Supplementary information. 371 
Peripheral T-cell phenotype  372 
There were no differences in absolute numbers or proportions of circulating naïve or effector/memory 373 
CD4 and CD8 T-cell subsets, or in cells within these subsets expressing α4β7, between diet groups at the 374 
end of the trial (online supplementary Table 5). Although there was no difference in the total number of 375 
Vδ2 T cells between groups, there were significantly fewer α4β7 positive Vδ2 T cells following low 376 
FODMAP compared to sham diet (online supplementary Table 5). 377 
  378 
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Discussion 379 
This is the first randomized, placebo-controlled trial demonstrating that low FODMAP dietary advice 380 
improves aspects of gut symptoms and HR-QOL in patients with quiescent IBD compared to sham dietary 381 
advice. Low FODMAP diet did not alter overall microbiome diversity or any species or strains on an 382 
untargeted analysis, though it altered some immune-regulatory components of the GI microbiome during 383 
a targeted analysis. Nonetheless, there was no impact on clinical disease activity or markers of 384 
inflammation.  385 
The finding of no significant difference in change in IBS-SSS despite higher rates of adequate relief 386 
following low FODMAP diet contrasts with a recent trial in IBS that reported a significant reduction in IBS-387 
SSS but no difference in adequate relief (9). The effectiveness of low FODMAP diet in the current trial 388 
confirms the findings of a non-blinded RCT in IBD in which more patients responded to low FODMAP diet 389 
than the normal diet group (13), although the IBS-SSS response rate to low FODMAP diet in the current trial 390 
was significantly lower, which likely relates to the lack of blinding in the previous trial.  391 
The subgroup of patients with UC, but not CD, reported a significantly greater reduction in IBS-SSS score 392 
after low FODMAP compared to sham diet. Differing efficacy of drug (42) and dietary (43) interventions has 393 
been demonstrated between CD and UC previously, and may be explained by differing disease 394 
pathophysiology and location. Furthermore, patients with CD are more likely to have intestinal 395 
inflammation not detected through fecal calprotectin (44), which could have abrogated GI symptom 396 
responses to the diet. This sub-group analysis although planned a priori should be interpreted with caution 397 
since the trial was not powered for this comparison.  398 
As expected from the proposed mechanism of action of low FODMAP diet, and consistent with previous 399 
studies in both IBS and IBD (9, 13, 15, 45), the greatest impact was on bloating and flatulence. Interestingly, 400 
abdominal pain was not different between diet groups following the diet. Unlike IBS, there is only limited 401 
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evidence that abdominal pain in quiescent IBD relates to luminal distension (46). Furthermore, at trial entry, 402 
62% of participants fulfilled functional bloating or functional diarrhea criteria, but not IBS, and therefore 403 
had minimal abdominal pain.  404 
In both the untargeted and targeted microbiome analyses, the abundance of fecal Bifidobacterium 405 
longum, B. adolescentis and total F. prausnitzii were lower following low FODMAP compared with sham 406 
diet, in agreement with the findings of some previous IBS trials (9, 16) but in contrast with a previous trial in 407 
which no changes in these bacteria were demonstrated in a small (n=9) sub-group of patients with Crohn’s 408 
disease following low FODMAP diet (21). Following adjustment for multiple comparisons, these findings 409 
remained significant in only the targeted microbiome analysis, as a result of fewer comparisons. These 410 
microbial alterations are likely a result of changes in colonic fermentable substrate; Bifidobacteria 411 
preferentially ferment fructans and GOS, while F. prausnitzii indirectly utilizes them through cross-feeding 412 
(47).  413 
The reduction in Bifidobacteria and F. prausnitzii during low FODMAP diet are of potential concern as 414 
these bacteria have immune-regulatory effects, including consistent evidence that Bifidobacteria and F. 415 
prausnitzii increase peripheral blood mononuclear cell (PBMC) IL-10 production in vitro  (18, 48). 416 
Furthermore, F. prausnitzii is associated with lower post-operative Crohn’s disease recurrence (18). Despite 417 
this, there were no detrimental effects of low FODMAP diet on fecal calprotectin or CRP. The lower 418 
proportion of α4β7+ Vδ2+ T-cells following low FODMAP diet may relate to variability in and the possible 419 
effect of thiopurine exposure on Vδ2+ T-cell numbers between individuals (49), since there was no 420 
difference in absolute numbers of this T-cell subgroup between diet groups.  421 
The lack of effect of low FODMAP diet on inflammation, despite microbiome alterations, may be explained 422 
in several ways. Firstly, much of the evidence of immune-regulatory effects of F. prausnitzii relate to strain 423 
A2-165 (18, 50), which was not different between diet groups. Secondly, other GI bacteria, such as Roseburia 424 
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intestinalis and Lactobacillus species, also exert immune-modulatory effects and were not altered by the 425 
diet (48, 51). Finally, the impact of longer-term restriction on inflammation in IBD is unknown since trial 426 
duration was four weeks.  427 
Abundance of hydrogen-consuming Adlercreutzia equolifaciens was higher following low FODMAP 428 
compared with sham diet, confirming findings in IBS (52). An emerging hypothesis is that low FODMAP diet 429 
may reduce luminal gas through both reduced fermentation and increased abundance of hydrogen-430 
consuming bacteria, however this requires confirmation.  431 
The reduced SCFA concentrations in UC specifically may be explained by differences in baseline 432 
microbiome composition between UC and CD (53) and also the greater GI symptom responses to low 433 
FODMAP diet in UC. Furthermore, since the colon is the site of SCFA generation, the degree of colonic 434 
disease involvement may contribute to differences in SCFA generation between CD and UC. It is tempting 435 
to speculate that the UC microbiome possesses greater saccharolytic potential, which is thus more likely 436 
to respond to reduced fermentable substrate with a decline in GI symptoms and a concomitant decline in 437 
SCFA. However, this requires confirmation in studies powered to detect differential effects of the diet in 438 
UC and CD.  439 
The analysis revealed differing abundance in numerous microbial genomic functional pathways between 440 
diet groups at end of trial. The abundance of acetyl-CoA to acetate pathway was lower following low 441 
FODMAP diet, in line with lower fecal acetate concentrations (supplementary information). Although fecal 442 
propionate concentrations were not affected by diet, the abundance of propionate production pathway 443 
was greater following low FODMAP diet.  444 
A major strength of this trial is that low FODMAP dietary advice was compared to sham dietary advice, 445 
providing the first placebo-controlled evidence of effectiveness in IBD. Unlike feeding studies, which are 446 
ideal for proof-of-concept, the current trial methodology assesses the effectiveness of a dietary 447 
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intervention as used in clinical practice. This trial also represents the first use of metagenomic sequencing 448 
providing a comprehensive assessment of GI microbiome composition and functional potential following 449 
low FODMAP diet. Furthermore, this is the first assessment of the effects of low FODMAP diet on immune 450 
function in IBD.  451 
The trial design did not permit blinding of the investigator to treatment allocation. Furthermore, the 452 
observed alterations in certain nutrient intakes following low FODMAP diet, as demonstrated in previous 453 
low FODMAP diet trials (54, 55), may be confounders in interpreting the effects of low FODMAP diet in this 454 
trial. Finally, although not all patients fulfilled the IBS criteria at baseline, the IBS-SSS was chosen for gut 455 
symptom assessment since it encompasses the predominant symptoms of IBS (abdominal pain/altered 456 
bowel habit), functional bloating (bloating/distension) and functional diarrhea (altered bowel habit).  457 
Quiescent IBD was defined, in part, as having fecal calprotectin ≤250 μg/g, as this has been shown to have 458 
optimal sensitivity and specificity for the identification of quiescent IBD (22). Theoretically, this may have 459 
resulted in recruitment of some participants with very mildly active disease. However, only 16/52 (31%) 460 
had a fecal calprotectin above 50 μg/g and 9/52 (17%) above 100 μg/g at enrolment, thus likely having 461 
minimal effects on trial outcomes.  462 
In conclusion, the first randomized, placebo-controlled dietary advice trial of low FODMAP diet in 463 
quiescent IBD reports improvement in some GI symptoms and HR-QOL. Despite a decline in Bifidobacteria 464 
and F. prausnitzii abundance, the diet did not adversely impact disease activity. Therefore, we propose 465 
that a 4-week low FODMAP diet with expert advice and intensive follow-up is safe and effective in the 466 
management of persistent gut symptoms in quiescent IBD, but caution should be taken in longer term 467 
use.   468 
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Tables 469 
Table 1 Baseline demographic and IBD characteristics of the study groups 470 
Variable Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Age (years) 33 (11) 40 (13) .031 
Male, n (%) 10 (37) 13 (52) .278 
BMI (kg/m2) 24 (3)  25 (4) .526 
Ethnicity, white, n (%) 25 (92) 19 (76) .029 
Rome III criteria, n (%)   .150 
IBS-D 10 (37) 5 (20)  
IBS-M 2 (7) 2 (8)  
IBS-U 0 (0) 1 (4)  
Functional bloating 15 (56) 13 (52)  
Functional diarrhoea 0 (0) 4 (16)  
Baseline IBS-SSS score 222 (76) 227 (81) .847 
Crohn’s disease, n (%) 14 (52) 12 (48) .781 
Time since diagnosis, years  7 (8) 11 (11) .187 
Montreal classification     
Crohn’s disease location, n (% of CD)   .773 
Ileal  4/14 (29) 2/12 (17)  
Colonic  4/14 (29) 4/12 (33)  
Ileocolonic 6/14 (42) 6/12 (50)  
Crohn’s disease behaviour, n (% of CD)   .949 
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Variable Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Non-stricturing, non-
penetrating  
9/14 (64) 8/12 (66)  
Stricturing  3/14 (21) 2/12 (17)  
Penetrating 2/14 (14) 2/12 (17)  
Perianal disease, n (% of CD) 4/14 (29) 3/12 (25) 1.000 
Ulcerative colitis extent, n (% of UC)   .403 
Proctitis 6/13 (46) 3/13 (23)  
Left-sided  4/13 (31) 7/13 (54)  
Extensive  3/13 (23) 3/13 (23)  
Medication, n (%)    
5-ASA  12 (44) 11 (44) .974 
Thiopurine 9 (33) 12 (48) .282 
Infliximab 10 (37) 4 (16) .087 
Adalimumab 2 (7) 4 (16) .411 
Vedolizumab  0 (0) 1 (4) .481 
Methotrexate  2 (7) 1 (4) 1.000 
Clinical symptoms    
 Total IBS-SSS score, mean (SD) 222 (76) 227 (81) .847 
Stool frequency, mean (SD) 1.8 (1.3) 2.1 (1.0) .282 
Stool consistency, proportion 
normal stools (type 3, 4, 5), 
mean (SD) 
66 (29) 64 (32) .869 
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Variable Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Continuous variables are presented as mean (SD) and were compared between groups using unpaired t-test, and 
categorical variables are presented as n (%) and were compared between groups using Chi-squared test 
471 
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Table 2 472 
IBS Severity Scoring System scores, global symptom question and stool frequency and consistency at end of trial 
 All participants Ulcerative colitis Crohn’s disease 
 Low FODMAP 
diet (n=27) 
Sham diet 
(n=25) 
P-
value 
Low FODMAP 
diet (n=13) 
Sham diet 
(n=13) 
P-
value 
Low FODMAP 
diet (n=14) 
Sham diet 
(n=12) 
P-
value 
Change in IBS-SSS score, mean (SEM) -67 (12) -34 (13) .075 -77 (15) -29 (15) .031 -55 (99) -42 (43) .515 
Total IBS-SSS score, mean (SEM) 158 (12) 190 (13) .075 135 (15) 183 (15) .031 170 (96) 208 (95) .515 
    Pain severity 22 (3) 30 (3) .098 20 (4) 29 (4) .123 24 (22) 32 (20) .475 
    Days of pain (days) 36 (5) 38 (5) .781 31 (6) 35 (6) .645 36 (37) 48 (37) .871 
    Bloating severity 23 (3) 34 (3) .021 21 (4) 31 (4) .113 22 (20) 39 (17) .071 
    Satisfaction with bowels 39 (3) 47 (4) .103 31 (5) 45 (5) .068 52 (18) 43 (26) .487 
    Impact on life  38 (3) 41 (3) .521 34 (4) 41 (4) .199 36 (25) 46 (25) .799 
IBS-SSS 50% reduction, n (%)  9 (33) 1 (4) .012 4 (31) 0 (0) .096 5 (36) 1 (8) .170 
Adequate relief, n (%) 14 (52) 4 (16) .007 7 (54) 2 (15) .097 7 (50) 2 (17) .110 
Stool frequency (per d), mean (SEM) 1.7 (0.1) 2.1 (0.1) .012 1.8 (0.1) 2.0 (0.1) .501 1.7 (0.1) 2.1 (0.1) .019 
Stool consistency          
    Daily BSFS score, mean (SEM) 4.3 (0.2) 4.4 (0.2) .606 4.0 (0.2) 4.4 (0.2) .191 4.6 (0.2) 4.4 (0.2) .673 
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 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
Stool consistency, proportion 
normal stools (Type 3, 4, 5), 
mean proportion (SEM) 
65 (5) 69 (5) .478 66 (6) 73 (6) .487 63 (6) 65 (7) .815 
Continuous variables are presented as estimated marginal mean (SEM) and were compared between groups using an ANCOVA with the corresponding baseline values as 
a covariate, and categorical variables are presented as n (%) and were compared between groups using Chi-squared test 
IBS-SSS, Irritable bowel syndrome severity scoring system; BSFS, Bristol Stool Form Scale 
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Table 3 Targeted microbiome analysis: relative abundance of Bifidobacteria species and 
Faecalibacterium prausnitzii strains between diet groups at end of trial 
 Low FODMAP diet 
(n=21) 
Sham diet 
(n=22) 
P-value Q-value 
Bifidobacteria (total) 8.63-7 (4.41-7) 3.19-6 (3.59-6) .073 -* 
Bifidobacterium adolescentis 1.99-7 (2.78-7) 2.55-6 (5.48-6) .003 .017 
Bifidobacterium longum 1.24-7 (1.81-7) 6.95-7 (1.03-6) .005 .017 
Bifidobacterium animalis 1.87-9 (8.59-9) 1.00-8 (4.58-8) .746 .768 
Bifidobacterium bifidum 6.77-8 (1.35-7) 1.79-7 (3.38-7) .066 .146 
Bifidobacterium breve 2.39-8 (1.09-7) 2.21-9 (1.09-7) .768 .768 
Bifidobacterium dentium 1.68-8 (5.23-8) 4.72-9 (1.75-8) .035 .096 
Bifidobacterium pseudocatenulatum 3.55-8 (1.17-7) 1.48-7 (4.42-7) .473 .651 
Faecalibacterium prausnitzii (total) 1.12-5 (1.42-5) 1.65-5 (1.35-5) .038 -* 
Faecalibacterium prausnitzii A2-165 2.33-6 (1.93-6) 2.81-6 (2.81-6) .186 .341 
Faecalibacterium prausnitzii SL3/3-M21/2 1.52-6 (2.08-6) 1.35-6 (1.68-6) .003 .017 
Faecalibacterium prausnitzii L2-6 3.61-6 (4.26-6) 1.30-6 (1.32-6) .750 .768 
Faecalibacterium prausnitzii cf. KLE1255 2.68-6 (3.48-6) 3.41-6 (3.89-6) .310 .488 
All data are presented as mean (SD) relative abundance and were compared between groups adjusted for 
baseline abundance and end of trial stool consistency  
*Total Bifidobacteria and Faecalibacterium prausnitzii abundance were not adjusted for multiple comparisons 
since these were analyzed separately at the genus level 
  481 
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Figures 482 
 483 
 484 
 485 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
Figure 1 CONSORT diagram of participant flow through the trial 503 
Low FODMAP diet (n=27) Placebo sham diet (n=25) 
Assessed for eligibility (n=155) 
Randomized (n=52) 
  
Excluded (screening 1) (n=98): 
Active IBD (7) 
Declined to participate or lost during 
screening (33) 
Symptoms not meeting Rome 
criteria (7) 
High FC or CRP (n=25) 
Antibiotics/probiotics (16) 
Comorbidity (1) 
Medication (5) 
Breastfeeding (1) 
Bile acid malabsorption (3) 
  
Included in the intention to 
treat analysis (n=27) 
Included in the intention to 
treat analysis (n=25) 
 
Included in per protocol analysis 
(n=24)  
3 excluded from the analysis: 
Withdrew consent (1) 
Antibiotics (1) 
Steroids (1) 
Included in the per protocol analysis 
(n=22): 
3 excluded from the analysis: 
Withdrew consent (1) 
Pregnancy (1) 
Steroids (1) 
Eligible (n=57) 
  
Excluded (screening 2) (n=5): 
Symptoms failed to meet required 
threshold (5) 
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Figure 2 Alpha and beta diversity and phyla distribution at end of trial. (A) microbial gene richness, (B) 517 
microbial species richness, (C) phyla distribution, (D) Shannon index, Simpson index and Bray-Curtis 518 
index 519 
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Figure 3 Untargeted microbiome analysis: fold difference in abundance of 29 species that were significantly different (P<.05) between diet 533 
groups at end of trial. None of these remained significant after FDR correction 534 
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 535 
Figure 4 Fold difference in abundance of 34 functional modules with significantly different (P<.05) abundance between diet groups at end of 536 
trial. None of these remained significant after FDR correction 537 
 538 
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Supplementary information 694 
Supplementary methods  695 
Microbiome composition and function  696 
The gene abundance profiling table was generated via a two-step procedure using METEOR. First, 697 
reads uniquely mapping to a gene in the catalogue were attributed to their corresponding genes. 698 
Second, reads mapped to multiple shared genes in the catalogue were attributed according to the 699 
ratio of the genes unique mapping counts. 700 
The gene abundance profiling table was generated via a two-step procedure using METEOR. First, 701 
reads uniquely mapping to a gene in the catalogue were attributed to their corresponding genes. 702 
Second, reads mapped to multiple shared genes in the catalogue were attributed according to the 703 
ratio of the genes unique mapping counts. 704 
The 9.9 million-gene catalogue was constructed by clustering 1436 MGS from 1267 human gut 705 
microbiome samples, as previously described (1). MGS abundances were estimated as the mean 706 
abundance of the 50 genes defining a robust centroid of the cluster. 707 
Supplementary results 708 
Gut symptoms 709 
The incidence of moderate or severe gastrointestinal symptoms and 7-day severity of symptoms (as 710 
assessed using the Gastrointestinal Symptom Rating Scale, GSRS) is presented in online supplementary 711 
Table 1. There were no differences between the diet groups in the incidence or severity of any 712 
symptoms, except for lower flatulence severity following low FODMAP compared to sham diet 713 
 714 
 715 
 716 
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 Incidence of moderate or severe symptomsa Severity of GI symptomsb 
Symptom Low FODMAP diet (n=27) Sham diet (n=25) P-value Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Pain  1.5 (0.3) 1.1 (0.3) .220 0.9 (0.5) 0.7 (4.5) .243 
Heartburn  0.3 (0.1) 0.2 (0.1) .514 0.2 (0.5) 0.1 (0.3) .344 
Acid regurgitation  0.3 (0.1) 0.2 (0.1) .359 0.2 (0.5) 0.2 (0.5) .504 
Nausea 0.5 (0.1) 0.3 (0.1) .283 0.3 (0.5) 0.3 (0.5) .335 
Gurgling 0.7 (0.2) 0.8 (0.2) .858 0.6 (0.5) 0.6 (0.5) .995 
Bloating 1.4 (0.3) 1.7 (0.3) .595 0.9 (0.5) 0.9 (0.5) .628 
Belching 0.2 (0.1) 0.5 (0.1) .141 0.4 (0.5) 0.5 (0.5) .312 
Flatulence 1.4 (0.3) 2.1 (0.4) .152 0.9 (0.5) 1.1 (0.6) .035 
Constipation 0.5 (0.2) 0.6 (0.2) .768 0.3 (0.5) 0.3 (0.5) .513 
Diarrhoea 0.4 (0.1) 0.5 (0.1) .507 0.2 (0.5) 0.3 (0.5) .214 
Loose stools 0.9 (0.2) 0.9 (0.2) .914 0.5 (0.5) 0.5 (0.5) .981 
Hard stools 0.1 (0.1) 0.3 (0.1) .293 0.2 (0.4) 0.2 (0.5) .656 
Urgency 0.9 (0.2) 0.8 (0.2) .756 0.6 (0.5) 0.5 (0.5) .635 
Incomplete evacuation 0.7 (0.2) 0.5 (0.2) .592 0.5 (0.5) 0.4 (0.5) .166 
Tiredness 2.3 (0.3) 2.0 (0.4) .692 1.1 (0.5) 1.0 (0.5) .694 
Online Supplementary Table 1 Incidence and severity of gastrointestinal symptoms, as measured by the Gastrointestinal Symptom Rating 
Scale, at end of trial 
 
39 
 
Overall symptoms 1.2 (0.5) 1.7 (0.7) .439 1.0 (0.5) 1.1 (0.5) .493 
Data are presented as estimated marginal mean (SEM) and groups were compared using ANCOVA with baseline values as a covariate 
a Number of days on which each symptom was reported at moderate or severe during the final week of the diet 
b Average severity across 7 days; 0=absent, 1=mild, 2=moderate, 3=severe 
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Dietary intake 717 
Daily intakes of energy, protein, fat, sugars, calcium, phosphorous and iodine were significantly lower 718 
following the low FODMAP compared to sham diet at end of trial (online supplementary Table 2).  719 
Online Supplementary Table 2 Daily intake of nutrients and FODMAPs in the diet groups at end of 720 
trial (7-day average intakes) 721 
 Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Energy (kcal/d) 1697 (47) 1918 (49) .002 
Protein (g/d) 74 (2) 83 (2) .008 
Fat (g/d) 68 (4) 80 (4) .035 
Saturated fat (g/d) 24 (1) 27 (2) .102 
Carbohydrate (g/d) 180 (6) 197 (6) .058 
Starch (g/d) 116 (4) 117 (5) .841 
Sugars (g/d) 63 (4) 76 (4) .022 
Fiber, AOAC (g/d) 17.8 (0.8) 19.2 (0.9) .249 
Calcium (mg/d) 692 (39) 911 (41) <.001 
Iron (mg/d) 10.9 (0.6) 12.0 (0.6) .170 
Zinc (mg/d) 9 (1) 10 (1) .470 
Sodium (mg/d) 1532 (85) 2195 (89) <.001 
Potassium (mg/d) 2938 (148) 3034 (154) .658 
Phosphorous (mg/d) 1140 (36) 1312 (37) .002 
Magnesium (mg/d) 290 (13) 297 (13) .709 
Iodine (μg/d) 124 (15) 176 (16) .022 
Selenium (μg/d) 59 (4) 57 (4) .823 
Vitamin A (μg/d) 1358 (207) 1328 (215) .921 
Vitamin C (mg/d) 90 (7) 75 (8) .166 
Vitamin D (μg/d) 6.4 (0.4) 6.3 (0.4) .818 
Vitamin B9 (folate) (μg/d) 229 (12) 257 (12) .110 
41 
 
 Low FODMAP diet (n=27) Sham diet (n=25) P-value 
Vitamin B12 (cobalamin) 
(μg/d) 
6.0 (0.9) 5.6 (0.9) .782 
FODMAPs    
Fructans (g/d) 1.3 (0.2) 2.9 (0.2) <.001 
GOS (g/d) 0.4 (0.1) 0.8 (0.1) <.001 
Lactose (g/d) 5.6 (1.0) 10.9 (1.1) .001 
Excess fructose (g/d) 0.5 (0.2) 1.4 (0.2) .001 
Sorbitol (g/d) 0.1 (0.1) 0.6 (0.1) .001 
Mannitol (g/d) 0.1 (0.0) 0.3 (0.0) .002 
Data are presented as estimated marginal mean (SEM) and groups were compared using ANCOVA with baseline 
values as a covariate. AOAC, Association of Official Analytical Chemists 
 722 
There were no differences in the proportion of patients meeting national macronutrient, 723 
micronutrient and fiber recommendations between the low FODMAP and sham diet groups at end of 724 
trial, or between baseline and end of trial in either diet group (data not shown).  725 
  726 
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Microbiome composition and SCFA 727 
Online supplementary table 3 displays the relative abundance of the bacterial species or strains that 728 
were significantly different between the diet groups at end of trial in the untargeted UC and CD sub-729 
group microbiome analyses.  730 
Online Supplementary Table 3 Untargeted microbiome analysis: relative abundance of species and 731 
strains that were significantly different between the diet groups (P≤.05) at end of trial in patients 732 
with ulcerative colitis and Crohn’s disease. None of these species were significantly different 733 
between diet groups after FDR correction 734 
 735 
 736 
 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
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 Ulcerative colitis Crohn’s disease 
Genus or species Low FODMAP diet 
(n=13)  
Sham diet 
(n=11) 
P-value Q-value Low FODMAP diet 
(n=8) 
Sham diet 
(n=11) 
P-value Q-value 
Bifidobacterium. adolescentis 1.52-7 (2.65-7) 1.72-7 (2.79-6) .004 .592 2.73-7 (3.02-7) 3.31-6 (7.19-6) .216 .690 
B. longum 1.60-7 (2.18-7) 7.21-7 (1.13-6) <.001 .115 6.53-8 (7.46-8) 6.73-7 (9.83-7) .201 .682 
F. prausnitzii         
SL3/3-M21/2 1.30-6 (1.93-6) 1.55-6 (1.47-6) .017 .592 1.87-6 (2.39-6) 1.17-6 (1.90-6) .031 .654 
A2-165 2.38-6 (2.02-6) 2.97-6 (2.35-6) .563 .806 2.26-6 (1.91-6) 2.66-6 (3.29-6) .094 .654 
L2-6 3.76-6 (4.67-6) 1.68-6 (1.19-6) .356 .693 3.37-6 (3.79-6) 9.56-7 (1.39-6) .443 .752 
KLE1255 3.63-6 (4.14-6) 4.43-6 (3.81-6) .562 .806 1.13-6 (8.88-7) 2.48-6 (3.89-6) .025 .654 
Ruminococcus sp. UNK.MGS-30 0.00 (0.00) 5.14-7 (9.13-7) .024 .592 0.00 (0.00) 0.00 (0.00) .393 .729 
Rumincoccus bicirculans 8.78-7 (2.18-6) 2.97-6 (5.15-6) .005 .592 1.40-6 (2.58-6) 1.05-6 (1.97-6) .984 .993 
Ruminococcaceae unclassified CAG00957 2.19-8 (7.21-8) 1.44-8 (3.49-8) .010 .592 1.63-9 (4.61-9) 1.31-7 (4.10-7) .475 .768 
Clostridium sp. AT4  4.91-7 (1.44-6) 5.35-8 (9.36-8) .015 .592 1.02-7 (2.10-7) 1.31-7 (3.51-7) .596 .849 
Clostridium unclassified CAG00441 3.44-8 (3.72-8) 7.92-8 (1.31-7) .107 .592 2.63-8 (1.89-8) 5.95-8 (1.30-7) .009 .563 
Clostridium bolteae 1.01-6 (2.99-6) 3.87-8 (4.40-8) .049 .592 5.41-8 (2.71-7) 2.04-7 (2.71-7) .800 .966 
Clostridium citroniae 8.52-8 (1.03-7) 3.21-8 (3.29-8) .799 .927 1.01-7 (1.03-7) 4.90-8 (6.40-8) .001 .311 
Clostridium sp. KLE 1755 9.04-8 (1.55-7) 2.80-8 (5.72-8) .201 .597 2.40-7 (2.70-7) 1.62-7 (4.46-7) .035 .654 
Clostridiales unclassified CAG01017 0.00 (0.00) 7.73-8 (1.25-7) .075 .592 1.17-8 (2.20-8) 4.98-8 (1.28-7) .049 .654 
Clostridiales unclassified CAG01281 2.42-8 (8.05-8) 1.57-8 (3.90-8) .006 .592 4.44-10 (1.26-9) 1.33-7 (4.39-7) .087 .654 
Roseburia intestinalis CAG00291 5.09-6 (8.80-6) 4.71-6 (8.35-6) .028 .592 2.98-6 (6.09-6) 6.39-7 (1.37-6) .300 .726 
Roseburia intestinalis CAG01369 4.94-6 (8.59-6) 4.42-6 (7.70-6) .032 .592 2.90-6 (5.94-6) 5.92-7 (1.27-6) .307 .726 
Roseburia unclassified CAG00869 7.95-8 (1.50-7) 5.65-8 (6.71-8) .649 .871 4.14-8 (8.93-8) 1.45-7 (2.47-7) .043 .654 
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 Ulcerative colitis Crohn’s disease 
Genus or species Low FODMAP diet 
(n=13)  
Sham diet 
(n=11) 
P-value Q-value Low FODMAP diet 
(n=8) 
Sham diet 
(n=11) 
P-value Q-value 
Flavonifractor sp. 2789STDY5834895 1.40-7 (1.55-7) 1.52-7 (1.71-7) .018 .592 2.44-7 (5.96-7) 4.12-7 (5.54-7) .148 .654 
Prevotella unclassified CAG00517 5.62-8 (2.03-7) 3.24-8 (1.03-7) .018 .592 0.00 (0.00) 1.37-6 (4.53-6) .335 .726 
Prevotella sp. CAG:520 8.29-7 (2.99-6) 4.38-7 (1.39-6) .018 .592 0.00 (0.00) 6.59-7 (2.19-6) .148 .654 
Eubacterium ventriosum 3.01-7 (5.45-7) 4.69-8 (7.85-8) .021 .592 3.74-8 (1.01-7) 3.86-7 (5.64-7) .043 .654 
Eubacterium hallii 2.02-7 (2.57-7) 1.66-7 (1.62-7) .369 .694 5.35-8 (6.15-8) 1.73-7 (1.57-7) .036 .654 
Catenibacterium mitsuokai 6.12-9 (2.21-8) 3.45-7 (1.09-6) .024 .592 1.25-7 (3.53-7) 0.00 (0.00) .311 .726 
Barnesiella intestinihominis 3.49-6 (5.64-6) 1.99-6 (2.93-6) .024 .592 2.73-6 (3.36-6) 3.97-6 (5.50-6) .638 .862 
Firmicutes unclassified CAG00808 9.75-8 (2.04-7) 1.62-8 (4.34-8) .886 .958 2.63-8 (3.74-8) 4.77-8 (1.01-7) .012 .654 
Firmicutes bacterium CAG:194  0.00 (0.00) 2.02-7 (4.02-7) .036 .592 0.00 (0.00) 4.25-7 (1.41-6) .402 .729 
Bacteroides xylanisolvens 2.57-6 (6.30-6) 1.66-6 (2.11-6) .481 .771 1.43-5 (2.43-5) 2.58-6 (4.99-6) .009 .563 
Bacteroides cellulosilyticus 1.46-7 (3.71-7) 1.59-8 (3.06-8) .038 .592 6.14-8 (1.74-7) 5.69-7 (1.10-6) .247 .706 
Parabacteroides distasonis 7.40-6 (1.61-5) 1.15-6 (9.61-7) .798 .927 3.99-6 (3.84-6) 3.25-6 (3.22-6) .007 .563 
Candidatus gastranaerophilales bacterium 
HUM_2 
1.16-6 (2.86-6) 2.07-7 (6.55-7) .032 .592 5.99-7 (1.69-6) 6.49-7 (2.11-6) .219 .693 
Coprobacter secundus 2.03-8 (4.44-8) 3.65-8 (7.37-8) .046 .592 1.80-7 (3.06-7) 2.63-8 (8.74-8) .195 .682 
Coprobacter fastidiosus 5.85-8 (1.37-7) 9.51-8 (1.95-7) .951 .975 3.04-9 (6.17-9) 2.57-7 (4.49-7) .027 .654 
Dorea longicatena 1 3.61-7 (5.35-7) 6.77-7 (9.24-7) .634 .860 1.19-7 (7.84-8) 5.72-7 (5.70-7) .001 .311 
Dorea longicatena 2 CAG00962 2.61-7 (6.72-7) 8.13-8 (1.16-7) .009 .592 3.93-8 (5.78-8) 1.27-7 (3.23-7) .353 .727 
Dorea formicigenerans 3.03-7 (2.85-7) 3.49-7 (2.13-7) .512 .785 1.00-7 (6.40-8) 2.02-7 (1.86-7) .005 .453 
Dorea sp. CAG:105 1.21-8 (1.92-8) 2.66-8 (3.73-8) .924 .973 1.12-8 (1.60-8) 2.13-8 (2.16-8) .021 .654 
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 Ulcerative colitis Crohn’s disease 
Genus or species Low FODMAP diet 
(n=13)  
Sham diet 
(n=11) 
P-value Q-value Low FODMAP diet 
(n=8) 
Sham diet 
(n=11) 
P-value Q-value 
Hungatella hathewayi 2 CAG00015 2.50-8 (2.60-8) 3.83-9 (9.37-9) .052 .592 2.56-8 (3.91-8) 9.46-9 (1.22-8) .021 .654 
Blautia unclassified CAG00235 1.74-7 (4.60-7) 9.77-9 (2.87-8) .108 .592 8.91-10 (2.52-9) 5.31-8 (9.61-8) .024 .654 
Anaerostipes hadrus  1.80-6 (5.47-8) 3.92-7 (3.28-7) .209 .597 1.48-7 (1.19-7) 6.37-7 (6.58-7) .005 .453 
Haemophilus parainfluenzae CAG00950 9.40-8 (1.32-7) 4.06-8 (7.41-8) .715 .901 1.24-7 (2.52-7) 2.49-8 (5.14-8) .002 .311 
Haemophilus parainfluenzae CAG01056 6.50-7 (1.08-6) 3.58-7 (6.93-7) .542 .798 9.61-7 (2.14-6) 1.94-7 (3.77-7) .033 .654 
Streptococcus thermophilus 4.93-8 (6.58-8) 1.59-8 (2.31-8) .245 .628 2.81-9 (7.95-9) 6.21-8 (1.48-7) .019 .654 
Massiliomicrobiota CAG00816 5.65-8 (1.75-7) 3.22-9 (7.35-9) .318 .660 0.00 (0.00) 8.64-9 (1.45-8) .025 .654 
Fusicatenibacter saccharivorans 1.26-6 (1.29-6) 1.00-6 (1.07-6) .704 .901 4.67-7 (2.90-7) 1.76-6 (1.73-6) .027 .654 
Eisenbergiella tayi  1.24-7 (3.02-7) 7.64-9 (1.36-8) .075 .592 2.28-7 (4.92-7) 1.69-8 (4.08-8) .019 .654 
Adlercreutzia equolifaciens 1.75-7 (2.18-7) 6.69-8 (7.42-8) .471 .762 2.76-8 (2.74-8) 5.54-8 (6.39-8) .003 .447 
Alistipes onderdonkii  9.11-7 (1.25-6) 4.06-7 (1.06-6) .015 .592 1.29-5 (2.68-5) 2.18-6 (4.41-6) .336 .726 
Intestinimonas massiliensis  1.08-7 (2.57-7) 1.71-9 (5.42-9) .023 .592 2.17-8 (3.66-8) 1.11-7 (2.41-7) .128 .654 
Lachnoclostridium unclassified CAG00764 3.36-7 (6.64-7) 5.11-8 (9.28-8) .022 .592 1.37-7 (2.56-7) 2.17-7 (3.47-7) .307 .726 
Unclassified CAG00420 2.69-8 (5.38-8) 7.54-8 (1.63-7) .024 .592 1.43-8 (2.85-8) 5.85-8 (1.17-7) .128 .654 
Data are presented as mean (SD) relative abundance and were compared between groups adjusted for baseline abundance and end of trial stool consistency 748 
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There were no differences in α-diversity or β-diversity between the diet groups in UC or CD (data not 750 
shown).  751 
There were no differences in concentrations of individual fecal short-chain fatty acids (SCFA) between 752 
diet groups at end of trial in the ITT population (online supplementary Table 4). However, in the PP 753 
population, there were significantly lower concentrations of total SCFA following low FODMAP diet 754 
compared to sham diet (online supplementary table 4). Specifically, fecal acetate was significantly 755 
lower following low FODMAP diet compared to sham diet.  756 
In patients with UC on the low FODMAP diet, compared to sham diet, there were lower concentrations 757 
of acetate (209 mg/100g, SD 109 vs. 328 mg/100g, SD 154, P=.037), butyrate (66 mg/100g, SD 40 vs. 758 
111 mg/100g, SD 75, P=.050) and valerate (6 mg/100g, SD 4 vs. 13 mg/100g, SD 10, P=.044) in the PP 759 
population. In patients with CD, there was a significantly lower end of trial isobutyrate concentration 760 
following the low FODMAP diet (7 SD 3 mg/100g) compared to the sham diet (11 mg/100g, SD 3, 761 
P=.024). There were no differences in the concentrations of any other individual SCFA in patients with 762 
CD in the PP population (data not shown). 763 
  764 
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Online Supplementary Table 4 Total and individual SCFA concentrations in the ITT and PP analysis 765 
 ITT analysis  PP analysis 
 Low FODMAP 
diet (n=27) 
Sham diet 
(n=25) 
P-value Low FODMAP diet 
(n=21) 
Sham diet 
(n=22) 
P- 
value 
Total SCFA  398 (192) 556 (245) .080 366 (174) 536 (251) .049 
Acetate 232 (117) 323 (138) .073 213 (109) 313 (140) .044 
Butyrate 67 (42) 92 (58) .102 62 (40) 86 (60) .094 
Propionate 76 (41) 108 (71) .190 69 (36) 104 (71) .138 
Valerate 7 (5) 11 (8) .169 7 (4) 10 (8) .164 
Isobutyrate 7 (3) 9 (6) .142 6 (3) 9 (6) .084 
Isovalerate 10 (5) 13 (9) .468 9 (4) 13 (9) .304 
pH 6.7 (0.6) 6.4 (0.6) .329 6.7 (0.6) 6.5 (0.6) .409 
Data are presented as estimated marginal mean (SEM) and were compared between groups using an ANCOVA 766 
with baseline values as a covariate 767 
Peripheral T-cell phenotype 768 
There were no differences in proportion of T-cells expressing α4β7 between diet groups in patients 769 
with UC. In CD there were significantly fewer naïve CD4+ T-cells (58.2%, SEM 4.5% vs. 79.8%, SEM 770 
5.7%; P=.008), naïve CD8+ T-cells (62.6%, SEM 4.0% vs. 76.4%, SEM 4.9%; P=.042) and 771 
effector/memory CD8+ T-cells (59.5%, SEM 3.0% vs. 70.3%, SD 3.7%; P=.036) expressing α4β7+ on low 772 
FODMAP compared to sham diet. 773 
  774 
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Online supplementary table 5 T-cell subset analysis: proportion of each population expressing 775 
α4β7+ and absolute number of α4β7+ cells at end of trial 776 
 Low FODMAP diet (n=27) Sham diet (n=23) P-value 
Naïve CD4+     
Proportion (%) 67.1 (2.9) 74.0 (3.2) .116 
Absolute 333,815 (4024) 279,761 (4466) .377 
Effector/memory CD4+     
Proportion (%) 38.7 (1.2) 41.1 (1.3) .164 
Absolute 166,034 (1634) 164,934 (1821) .965 
Naïve CD8+     
Proportion (%) 68.9 (2.5) 74.6 (2.7) .135 
Absolute 225,275 (2486) 172,076 (2759) .163 
Effector/memory CD8+     
Proportion (%) 63.6 (2.3) 69.9 (2.3) .054 
Absolute 81,845 (8812) 80,040 (9803) .894 
Vδ2+     
Proportion (%) 71.6 (2.0) 79.1 (2.2) .017 
Absolute 30,535 (3897) 31,140 (4419) .377 
Data are presented as estimated marginal mean (SEM) and were compared between groups using an ANCOVA 777 
with baseline values as a covariate 778 
Fecal calprotectin between baseline and end of trial 779 
There was no difference in fecal calprotectin concentrations between low FODMAP and sham diet 780 
groups at end of trial in either the CD (61.2 µg/g SEM 6.3 vs. 68.4 µg/g SEM 6.8, P=.448) or the UC 781 
(55.9 µg/g SEM 18.2 vs. 54.2 µg/g SEM 18.2, P=.950) sub-groups.  782 
49 
 
There were no differences in fecal calprotectin at baseline compared to end of trial in low FODMAP or 783 
sham diet groups, and the same was true for the UC and CD sub-groups (online supplementary Table 784 
6).  785 
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Online Supplementary Table 6 Baseline compared to end of trial fecal calprotectin concentrations in the low FODMAP and sham diet groups in 786 
all patients and the UC and CD sub-groups 787 
 All patients (low FODMAP n=27, sham n=25) UC (low FODMAP n=13, sham n=13) CD (low FODMAP n=14, sham n=12) 
 Baseline End of trial P-
value 
Baseline End of trial P-value Baseline End of trial P-
value 
Low FODMAP (µg/g) 54.8 (84.8) 53.3 (84.8) .857 21.9 (69.7) 10.9 (30.7) .087 22.8 (66.1) 35.2 (26.8) .674 
Sham (µg/g) 70.9 (117.3) 66.9 (106.4) .727 25.2 (67.3) 28.6 (67.7) .721 22.8 (52.5) 15.9 (87.8) .929 
Data are presented as median (interquartile range) and were compared between baseline and end of trial using a Wilcoxon signed rank test  788 
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